

Date: 11th October, 2021

BSE Limited
Corporate Service Department,
1st Floor, P. J. Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Limited
Exchange Plaza, 3rd Floor,
Plot No. C/1, 'G' Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

Scrip ID: KRSNAA
Scrip Code: 543328

Symbol: KRSNAA

Dear Sir / Madam,

Subject: Outcome of Board Meeting.

This is to inform you that the Board of Directors of the Company at its meeting held today, which commenced at 12:30 p.m. and concluded at 04:05 p.m., inter-alia, unanimously approved / consented / took on record the following:

Financial Results:

Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September, 2021, along with Limited Review report thereon. A copy of the same is enclosed.

Change in the Key Managerial Personnel:

The resignation of CS Manisha Chitgopekar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021 and appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015.

We have enclosed, the disclosure in terms of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure I to this letter.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332



Annexure I

Disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

A. Resignation of Ms. Manisha Chitgopekar:

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1	Reason for change viz. appointment, resignation, removal, death or otherwise:	Resignation due to health reasons.
2	Date of appointment/cessation (as applicable) & term of appointment:	Effective from closing of business hours on Monday, 11 th October, 2021.
3	Brief Profile (in case of appointment)	Not applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

B. Appointment of Mr. Nikhil Deshpande:

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1	Reason for change viz. appointment, resignation, removal, death or otherwise:	Appointment.
2	Date of appointment/cessation (as applicable) & term of appointment:	Effective from Tuesday, 12 th October, 2021.
3	Brief Profile (in case of appointment)	Nikhil has an experience of 10+ years in the Company Secretarial function including fund raising through IPO, Corporate Governance. Prior to joining Krsnaa, he has worked with leading listed companies like in Pune viz. Kinetic Engineering, Zensar Technologies as well as KPIT Technologies. He is a law graduate and an associate member of the Institute of Company Secretaries of India.
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Nikhil Deshpande is not related to any other Director(s) presently on the Board or any of the Key Managerial Personnel of the Company.




Independent Auditor’s Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

Krsnaa Diagnostics Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Krsnaa Diagnostics Limited (‘the Holding Company’), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the ‘Group’) for the quarter ended September 30, 2021 and the year to-date results for the period from April 01, 2021 to September 30, 2021 (‘the Statement’), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (‘the Regulations’). Attention is drawn to the fact that the figures for the previous quarter ended June 30, 2021, as reported in these consolidated financial results have been approved by the Company’s Board of Directors but have not been subjected to review.
2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’(‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
3	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (SAS Nagar) Private Limited	Wholly Owned Subsidiary
7	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary

5. The consolidated unaudited financial results include the interim financial information of Seven (7) subsidiaries which have not been reviewed by their auditors, whose interim financial information results reflect total assets of Rs. 2.69 million as at September 30, 2021 and total revenue of Rs. Nil and Rs. Nil, total net loss after tax of Rs. 0.13 million and Rs. 0.23 million and total comprehensive loss of Rs. 0.13 million and Rs. 0.23 million for the quarter ended September 30, 2021 and for the period from April 01, 2021 to September 30, 2021, respectively, and cash inflows of Rs. 2.28 million for the period from April 01, 2021 to September 30, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.



MSKA

& Associates

Chartered Accountants

Our conclusion on the Statement is not modified in respect of the above matter.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Digitally signed
by Nitin Jumani
Date:
2021.10.11
14:56:57
+05:30



Nitin Manohar Jumani

Partner

Membership No.: 111700

UDIN: 21111700AAAAFO5907

Place: Pune

Date: October 11, 2021

Statement of Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2021

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended		Half Year ended
		September 30, 2021	June 30, 2021	September 30, 2021
		(Unaudited)	(Unaudited / Unreviewed - Refer Note 7)	(Unaudited)
1	Income			
	Revenue from operations	1,082.63	1,324.72	2,407.35
	Other income	32.30	32.38	64.68
	Total Income	1,114.93	1,357.10	2,472.03
2	Expenses			
	Cost of material consumed	135.88	222.59	358.47
	Employee benefits expense	128.17	124.09	252.26
	Finance costs	82.14	61.21	143.35
	Depreciation and amortization expense	103.32	99.76	203.08
	Fees to hospitals and others	274.13	283.11	557.24
	Other expenses	225.09	279.87	504.96
	Total Expenses	948.73	1,070.63	2,019.36
3	Profit / (loss) before tax (1) - (2)	166.20	286.47	452.67
4	Tax expenses			
	Income Tax charge	28.93	49.84	78.77
	Deferred tax charge/(credit)	12.01	20.68	32.69
	Total tax expenses	40.94	70.52	111.46
5	Profit / (loss) for the period/year (3) - (4)	125.26	215.95	341.21
6	Other comprehensive income			
	Items that will not be reclassified subsequently to profit and loss	-	-	-
	Re-measurement gains / (losses) on defined benefit plans	(0.10)	(0.10)	(0.20)
	Income tax effect	0.02	0.02	0.04
	Total other comprehensive income/(loss) for the period/year	(0.08)	(0.08)	(0.16)
7	Total comprehensive income/(loss) for the period/year, net of tax (5+6)	125.18	215.87	341.05
	Profit/(loss) for the period/year			
	Attributable to:			
	Equity Holders of the Holding Company	125.26	215.95	341.21
	Non Controlling Interests	-	-	-
		125.26	215.95	341.21
	Total other comprehensive income/(loss) for the period/year			
	Attributable to:			
	Equity Holders of the Holding Company	(0.08)	(0.08)	(0.16)
	Non Controlling Interests	-	-	-
		(0.08)	(0.08)	(0.16)
	Total comprehensive income/(loss) for the period/year			
	Attributable to:			
	Equity Holders of the Holding Company	125.18	215.87	341.05
	Non Controlling Interests	-	-	-
		125.18	215.87	341.05
8	Paid-up equity share capital (Face Value of Rs. 5/- Each)	156.99	64.95	156.99
	Earnings per share - After split (Not annualised for quarter & half year)			
	Basic (Rs.)	4.51	16.62	12.28
	Diluted (Rs.)	4.47	7.94	12.17

Place: Pune
Date: 11.10.2021



For & on behalf of Board
Krsnaa Diagnostics Limited

P. Bhatevara
Pallavi Bhatevara
Managing Director
DIN: 03600332

Krsnaa Diagnostics Limited
(Formerly known as Krsnaa Diagnostics Private Limited)

Notes to Unaudited Consolidated Financial Results:

1. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at its meeting held on October 11, 2021.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Holding Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 & consequently the name of the Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh certificate of Incorporation issued by Registrar of Company dated May 6, 2021.
4. The Holding company has invested into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathinda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 25, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 25, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021

The company has remitted the amount towards subscription of share capital in these SPVs on April 12, 2021 & August 21, 2021. In the absence of the necessary agreement being executed and transfer of funds for subscription of share capital of these subsidiaries by March 31, 2021 the Holding Company has not consolidated the SPVs in its financial statement for the year ended March 31, 2021.
5. The Holding Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided its equity share capital by sub-dividing the face value of the Equity Shares from ₹10 to ₹5 per Equity Share. Accordingly, the issued and paid-up capital of our Company was sub-divided from 6,494,964 Equity Shares of ₹10 each to 12,989,928 Equity Shares of ₹5 each.
6. Pursuant to resolution passed at the meeting of Board of Director's held on July 23, 2021, 1,42,01,600 equity shares were issued to compulsory convertible preference shareholders of series A and series C in the ratio 2:1
7. The Holding Company has completed Initial Public Offer (IPO) of 1,27,31,605 Equity Shares of the face value of Rs. 5/- each at an issue price of Rs. 954/- per Equity Share to non employee category shareholders and Rs. 861/- per Equity Share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The Equity Shares of the Company were listed on August 16, 2021 on BSE Limited and National Stock Exchange of India Limited. The total offer expenses have been proportionately allocated between the selling shareholders and the Holding Company as per respective offer size.


The Holding Company was not mandatorily required to prepare and publish quarterly results up to the period ended June 30, 2021. Accordingly, the figures for the quarter ended June 30, 2021 have been approved by the Company's board of director but were not subject to limited review or audit by the statutory auditors of the company.
8. The Group's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, Tele- Reporting Services, and all type of Blood and Urine Investigation. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence no separate segment information has been furnished herewith.
9. The management has made an assessment of the impact of COVID-19 on the Group operations, financial performance and position as at and for the quarter & six months ended September 30, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results.
10. The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Group will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
11. Previous period figures have been regrouped/ rearranged wherever considered necessary.

Place: Pune
Date: 11.10.2021



For & on behalf of Board
Krsnaa Diagnostics Limited


Pallavi Bhatevara
Managing Director
DIN: 03600332

Krsnaa Diagnostics Limited (Formerly known as Krsnaa Diagnostics Private Limited)	
Consolidated Balance Sheet as at September 30, 2021	
(INR Million.)	
Particulars	As at September 30, 2021 (Unaudited)
I. ASSETS	
Non-current assets	
Property, plant and equipment	3,063.02
Capital work-in-progress	195.23
Intangible assets	7.30
Financial assets	
Investments	2.90
Loans	145.59
Other financial assets	2.81
Other non-current assets	202.32
Total non-current assets	3,619.17
Current assets	
Inventories	95.50
Financial assets	
Trade receivables	1,070.04
Cash and cash equivalents	343.10
Bank balances other than cash and cash equivalent	3,454.14
Other financial assets	91.63
Other current assets	96.30
Total current assets	5,150.71
Total Assets	8,769.88
II. EQUITY AND LIABILITIES	
Equity	
Equity share capital	156.99
Other equity	6,291.97
Non-controlling interest	-
Total equity	6,448.96
Liabilities	
Non-current liabilities	
Financial liabilities	
Borrowings	362.03
Other financial liabilities	67.29
Employee benefit obligations	6.14
Other non-current liabilities	29.48
Deferred Tax Liabilities	139.59
Total non-current liabilities	604.53
Current liabilities	
Financial liabilities	
Borrowings	128.55
Trade payables	
i)total outstanding dues of micro enterprises and small enterprises	4.36
ii)total outstanding dues of creditors other than micro enterprise and small enterprise	952.07
Other financial liabilities	242.64
Employee benefit obligations	9.17
Other current liabilities	379.60
Total current liabilities	1,716.39
Total Liabilities	2,320.92
Total Equity and Liabilities	8,769.88
Place: Pune Date: 11.10.2021	 <p>For & on behalf of Board Krsnaa Diagnostics Limited</p> <p><i>P. Bhatevara</i> Pallavi Bhatevara Managing Director DIN: 03600332</p>

Krsnaa Diagnostics Limited
(Formerly known as Krsnaa Diagnostics Private Limited)

Statement of Consolidated Cash Flows for the Half year ended September 30, 2021

(INR Million.)

Particulars	Six Months ended
	September 30, 2021 (Unaudited)
Cash flow from operating activities	
Profit/(Loss) for the period	452.67
Adjustments for:	
Depreciation and amortization expenses	203.08
Finance cost	143.35
Interest income	(52.08)
Loss on Sale/Disposal of Assets	-
Provision for doubtful trade receivable balances	5.45
Gain on fair value movement of Compulsory Convertible Preference Share	-
Employee stock option scheme compensation	7.25
Operating profit before working capital changes	759.72
Changes in working capital	
(Decrease)/increase in trade payables	32.06
Decrease/(increase) in inventories	(23.40)
Decrease/(increase) in trade receivables	(350.92)
(Decrease)/Increase in other current liabilities	340.48
(Decrease)/ increase in other non current liabilities	(3.55)
(Decrease)/ increase in other financial liabilities	3.40
(Decrease)/ increase in Employee Payables	0.64
(Decrease)/ increase in provisions	-
(Decrease)/ increase in other current financial liabilities	(3.96)
Decrease/(increase) in other current financial assets	(29.33)
Decrease/(increase) in non current financial assets	(10.15)
Decrease/(increase) in other current assets	(3.04)
Decrease/(increase) in other non current assets	4.83
Cash generated from/(used) in operations	716.78
Income tax paid	(69.71)
Income tax refund received	82.01
Net cash flows generated from/(used) in operating activities (A)	729.08
B. Cash flow from Investing activities	
Payment for property, plant and equipment and intangible assets	(530.45)
Proceeds from sale of property, plant and equipment and intangible assets	-
Investment in term deposits with banks (having original maturity of more than three months)	(2,150.51)
Interest received	79.89
Net cash flow (used) in investing activities (B)	(2,601.07)
C. Cash flow from Financing activities	
Proceeds from Issuance of equity share capital	4,000.00
Proceeds/(Repayment) of borrowings	(1,779.34)
Share Issue expenses	(107.14)
Interest paid	(145.18)
Net cash flow generated from/(used) in financing activities (C)	1,968.34
Net increase in cash and cash equivalents (A+B+C)	96.35
Cash and cash equivalents at the beginning of the period	246.75
Cash and cash equivalents at the end of the period	343.10
Cash and cash equivalents comprise:	
Balances with banks	
On current accounts	332.46
Bank Overdraft Account (Debit Balance)	0.33
Cash on hand	10.31
Less: Bank and book overdraft	-
Total cash and bank balances at end of the period	343.10

Place: Pune
Date: 11.10.2021



For & on behalf of Board
Krsnaa Diagnostics Limited

P. B. Lakshmi
Pallavi Bhatevara
Managing Director
DIN: 03600332

Independent Auditor’s Review Report on unaudited quarterly and year to date standalone financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

Krsnaa Diagnostics Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krsnaa Diagnostics Limited (‘the Company’) for the quarter ended September 30, 2021 and the year to-date results for the period April 01, 2021 to September 30, 2021 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (‘ the Regulation’). Attention is drawn to the fact that the figures for the previous quarter ended June 30, 2021, corresponding quarter ended and six months ended September 30, 2020, as reported in these standalone financial results have been approved by the Company’s Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether standalone financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W



Digitally signed
by Nitin Jumani
Date:
2021.10.11
14:58:44
+05:30



Nitin Manohar Jumani

Partner

Membership No.: 111700

UDIN: 2111700AAAAFN9972

Place: Pune

Date: October 11, 2021

Statement of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2021

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year Ended
		September 30, 2021	June 30, 2021	September 30, 2020	September 30, 2021	September 30, 2020	March 31, 2021
		(Unaudited)	(Unaudited / Unreviewed - Refer Note 6)	(Unaudited / Unreviewed - Refer Note 6)	(Unaudited)	(Unaudited / Unreviewed - Refer Note 6)	Audited
1	Income						
	Revenue from operations	1,082.63	1,324.72	1,501.59	2,407.35	2,026.94	3,964.56
	Gain on fair value movement of Compulsory Convertible Preference Share	-	-	-	-	2,527.84	2,527.84
	Other income	32.30	32.38	35.33	64.68	65.31	122.36
	Total Income	1,114.93	1,357.10	1,536.92	2,472.03	4,620.09	6,614.76
2	Expenses						
	Cost of material consumed	135.88	222.59	376.69	358.47	522.50	837.47
	Employee benefits expense	128.17	124.09	83.91	252.26	138.06	295.86
	Finance costs	82.02	61.10	63.94	143.12	132.46	259.40
	Depreciation and amortization expense	103.32	99.76	93.63	203.08	179.09	374.39
	Fees to hospitals and others	274.13	283.11	404.24	557.24	579.36	1,082.02
	Other expenses	225.09	279.87	209.22	504.96	368.51	811.10
	Total Expenses	948.61	1,070.52	1,231.63	2,019.13	1,919.98	3,660.24
3	Profit / (loss) before tax (1) - (2)	166.32	286.58	305.29	452.90	2,700.11	2,954.52
4	Tax expenses						
	Income Tax charge	28.93	49.84	54.27	78.77	30.62	76.47
	Deferred tax charge/(credit)	12.01	20.68	24.78	32.69	1,007.89	1,028.76
	Total tax expenses	40.94	70.52	79.05	111.46	1,038.51	1,105.23
5	Profit / (loss) for the period/year (3) - (4)	125.38	216.06	226.24	341.44	1,661.60	1,849.29
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss						
	Re-measurement gains / (losses) on defined benefit plans	(0.10)	(0.10)	(0.10)	(0.20)	(0.20)	(0.38)
	Income tax effect	0.02	0.02	0.02	0.04	0.04	0.10
	Total other comprehensive income/(loss) for the period/year	(0.08)	(0.08)	(0.08)	(0.16)	(0.16)	(0.28)
7	Total comprehensive income/(loss) for the period/year, net of tax (5+6)	125.30	215.98	226.16	341.28	1,661.44	1,849.01
8	Paid-up equity share capital (Face Value of Rs. 10/- each as on March 31, 2021 and September 30, 2020 and Rs. 5/ each as on June 30, 2021 and September 30, 2021)	156.99	64.95	51.63	156.99	51.63	64.95
	Instruments entirely equity in nature						2,423.90
	Other equity						(170.20)
	Earnings per share - After Split (Not annualised for quarters & half years)						
	Basic (Rs.)	4.51	16.63	21.91	12.29	160.91	160.36
	Diluted (Rs.)	4.47	7.95	9.22	12.18	5.20	12.25



Krsnaa Diagnostics Limited
(Formerly known as Krsnaa Diagnostics Private Limited)

Notes to Unaudited Standalone Financial Results:

1. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 11, 2021.
 2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
 3. The Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 & consequently the name of the Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh certificate of Incorporation issued by Registrar of Company dated May 6, 2021.
 4. The Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided its equity share capital by sub-dividing the face value of the Equity Shares from ₹10 to ₹5 per Equity Share. Accordingly, the issued and paid-up capital of our Company was sub-divided from 6,494,964 Equity Shares of ₹10 each to 12,989,928 Equity Shares of ₹5 each.
 5. Pursuant to resolution passed at the meeting of Board of Director's held on July 23, 2021, 1,42,01,600 equity shares were issued to compulsory convertible preference shareholders of series A and series C in the ratio 2:1
 6. The Company has completed Initial Public Offer (IPO) of 1,27,31,605 Equity Shares of the face value of Rs. 5/- each at an issue price of Rs. 954/- per Equity Share to non employee category shareholders and Rs. 861/- per Equity Share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The Equity Shares of the Company were listed on August 16, 2021 on BSE Limited and National Stock Exchange of India Limited. The total offer expenses have been proportionately allocated between the selling shareholders and the Company as per respective offer size.
- The Company was not mandatorily required to prepare and publish quarterly results up to the period ended June 30, 2021. Accordingly, the figures for the corresponding quarter & six months ended September 30, 2020 and quarter ended June 30, 2021 have been approved by the Company's board of director but were not subject to limited review or audit by the statutory auditors of the company.
7. The company has invested into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathinda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 25, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 25, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021
- The company has remitted the amount towards subscription of share capital in these SPVs on April 12, 2021 & August 21, 2021.
8. The Company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, Tele- Reporting Services, and all type of Blood and Urine Investigation. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence no separate segment information has been furnished herewith.
 9. The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the quarter & six months ended September 30, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results.
 10. The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
 11. Previous period figures have been regrouped/ rearranged wherever considered necessary.

Place: Pune
Date: 11.10.2021



For & on behalf of Board
Krsnaa Diagnostics Limited


Pallavi Bhatevara
Managing Director
DIN: 03600332

Krsnaa Diagnostics Limited
(Formerly known as Krsnaa Diagnostics Private Limited)

Standalone Balance Sheet as at September 30, 2021

(INR Million.)

Particulars	As at September 30, 2021 (Unaudited)	As at March 31, 2021 (Audited)
I. ASSETS		
Non-current assets		
Property, plant and equipment	3,063.02	3,072.80
Capital work-in-progress	195.23	37.18
Intangible assets	7.30	12.28
Financial assets		
Investments	3.60	2.90
Loans	145.59	135.44
Other financial assets	2.81	24.08
Other non-current assets	202.32	279.24
Total non-current assets	3,619.87	3,563.92
Current assets		
Inventories	95.50	72.10
Financial assets		
Trade receivables	1,070.04	724.74
Cash and cash equivalents	340.82	246.75
Bank balances other than cash and cash equivalent	3,454.14	1,282.37
Other financial assets	93.40	90.08
Other current assets	95.89	65.34
Total current assets	5,149.79	2,481.38
Total Assets	8,769.66	6,045.30
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	156.99	64.95
Instruments entirely equity in nature	-	2,423.90
Other equity	6,292.20	(170.20)
Total equity	6,449.19	2,318.65
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	362.03	1,679.54
Other financial liabilities	67.29	63.89
Employee benefit obligations	6.14	5.19
Other non-current liabilities	29.48	33.03
Deferred Tax Liabilities	139.59	106.95
Total non-current liabilities	604.53	1,888.60
Current liabilities		
Financial liabilities		
Borrowings	128.55	347.44
Trade payables		
i) total outstanding dues of micro enterprises and small enterprises	4.36	5.37
ii) total outstanding dues of creditors other than micro enterprise and small enterprise	952.07	780.19
Other financial liabilities	242.64	665.54
Employee benefit obligations	9.17	9.28
Other current liabilities	379.15	30.23
Total current liabilities	1,715.94	1,838.05
Total Liabilities	2,320.47	3,726.65
Total Equity and Liabilities	8,769.66	6,045.30



For & on behalf of Board
Krsnaa Diagnostics Limited

Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: 11.10.2021

Statement of Standalone Cash Flows for the Half year ended September 30, 2021

(INR Million.)

Particulars	Half year ended		Year Ended
	September 30, 2021	September 30, 2020	March 31, 2021
	(Unaudited)	(Unaudited / Unreviewed - Refer Note 6)	(Audited)
A. Cash flow from operating activities			
Profit/(Loss) for the period	452.90	2,700.11	2,954.52
Adjustments for:			
Depreciation and amortization expenses	203.08	179.09	374.39
Finance cost	143.12	132.46	259.40
Interest income	(52.08)	(51.46)	(119.38)
Loss on Sale/Disposal of Assets	-	-	5.06
Provision for doubtful trade receivable balances	5.45	-	-
Gain on fair value movement of Compulsory Convertible Preference Share	-	(2,527.84)	(2,527.84)
Employee stock option scheme compensation	7.25	2.29	8.20
Operating profit before working capital changes	759.72	434.65	954.35
Changes in working capital			
(Decrease)/increase in trade payables	32.06	472.53	404.62
Decrease/(increase) in inventories	(23.40)	(56.75)	(21.43)
Decrease/(increase) in trade receivables	(350.92)	(372.77)	(110.42)
(Decrease)/increase in other current liabilities	340.03	(4.94)	12.51
(Decrease)/ increase in other non current liabilities	(3.55)	(3.73)	(12.94)
(Decrease)/ increase in other financial liabilities	3.40	(6.10)	(143.85)
(Decrease)/ increase in Employee Payables	0.64	1.30	(0.38)
(Decrease)/ increase in provisions	-	-	4.05
(Decrease)/ increase in other current financial liabilities	(3.96)	27.77	-
Decrease/ (increase) in other current financial assets	(31.11)	85.98	118.90
Decrease/ (increase) in non current financial assets	(10.15)	(34.82)	(31.16)
Decrease/ (increase) in other current assets	(2.61)	(23.42)	(50.44)
Decrease/ (increase) in other non current assets	4.82	6.22	(21.51)
Cash generated from/(used) in operations	714.97	525.92	1,102.30
Income tax paid	(69.71)	(30.62)	(76.73)
Income tax refund received	82.01	34.54	-
Net cash flows generated from/(used) in operating activities (A)	727.27	529.84	1,025.57
B. Cash flow from Investing activities			
Payment for property, plant and equipment and intangible assets	(530.45)	(329.55)	(668.40)
Proceeds from sale of property, plant and equipment and intangible assets	-	-	20.00
Investment in term deposits with banks (having original maturity of more than three months)	(2,150.51)	(14.99)	(56.97)
Investments in subsidiaries	(0.70)	-	-
Interest received	79.89	1.05	93.98
Net cash flow (used) in investing activities (B)	(2,601.77)	(343.49)	(611.39)
C. Cash flow from Financing activities			
Proceeds from issuance of equity share capital	4,000.00	-	7.31
Proceeds/(Repayment) of borrowings (net)	(1,779.34)	28.92	555.27
Share issue expenses	(107.14)	-	-
Interest paid	(144.95)	(120.92)	(254.17)
Net cash flow generated from/(used) in financing activities (C)	1,968.57	(92.00)	308.41
Net increase in cash and cash equivalents (A+B+C)	94.07	94.35	722.59
Cash and cash equivalents at the beginning of the period	246.75	(475.84)	(475.84)
Cash and cash equivalents at the end of the period	340.82	(381.49)	246.75
Cash and cash equivalents comprise:			
Balances with banks			
On current accounts	330.18	39.05	237.98
Bank Overdraft Account (Debit Balance)	0.33	-	3.12
Cash on hand	10.31	23.48	5.65
Less: Bank and book overdraft	-	(444.02)	-
Total cash and bank balances at end of the period	340.82	(381.49)	246.75

Place: Pune
Date: 11.10.2021



For & on behalf of Board
Krsnaa Diagnostics Limited

P. Bhatnagar
Pallavi Bhatnagar
Managing Director
DIN: 03600332